UM
Current strategies for treating NSCLC: From biological mechanisms to clinical treatment
Li,Junnan1; Kwok,Hang Fai1,2
2020-06-01
Source PublicationCancers
Volume12Issue:6Pages:1-24
AbstractThe identification of specific epidermal growth factor receptor (EGFR)-activating mutations heralded a breakthrough in non-small-cell lung cancer (NSCLC) treatments, with the subsequent development of EGFR-tyrosine kinase inhibitor (TKIs) becoming the first-line therapy for patients harboring EGFR mutations. However, acquired resistance to EGFR-TKIs inevitably occurs in patients following initial TKI treatment, leading to disease progression. Various mechanisms are behind the acquired resistance, and mainly include (1) target gene modification, (2) alternative parallel pathway activation, (3) downstream pathway activation, and (4) histological/phenotypic transformation. Approaches to combat the acquired resistance have been investigated according to these mechanisms. Newer generations of TKIs have been developed to target the secondary/tertiary EGFR mutations in patients with acquired resistance. In addition, combination therapies have been developed as another promising strategy to overcome acquired resistance through the activation of other signaling pathways. Thus, in this review, we summarize the mechanisms for acquired resistance and focus on the potential corresponding therapeutic strategies for acquired resistance.
KeywordCombination targeted therapy Drug resistance mechanism EGFR mutation Lung cancer
DOI10.3390/cancers12061587
URLView the original
Language英语
Fulltext Access
Citation statistics
Cited Times [WOS]:5   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionUniversity of Macau
Corresponding AuthorKwok,Hang Fai
Affiliation1.Cancer Centre,Faculty of Health Sciences,University of Macau,Taipa,Avenida de Universidade,Macao
2.Institute of Translational Medicine,Faculty of Health Sciences,University of Macau,Taipa,Avenida de Universidade,Macao
First Author AffilicationCancer Centre
Corresponding Author AffilicationCancer Centre;  Faculty of Health Sciences
Recommended Citation
GB/T 7714
Li,Junnan,Kwok,Hang Fai. Current strategies for treating NSCLC: From biological mechanisms to clinical treatment[J]. Cancers,2020,12(6):1-24.
APA Li,Junnan,&Kwok,Hang Fai.(2020).Current strategies for treating NSCLC: From biological mechanisms to clinical treatment.Cancers,12(6),1-24.
MLA Li,Junnan,et al."Current strategies for treating NSCLC: From biological mechanisms to clinical treatment".Cancers 12.6(2020):1-24.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Li,Junnan]'s Articles
[Kwok,Hang Fai]'s Articles
Baidu academic
Similar articles in Baidu academic
[Li,Junnan]'s Articles
[Kwok,Hang Fai]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Li,Junnan]'s Articles
[Kwok,Hang Fai]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.